Clinical-stage neuroscience biotech developing gut-restricted neurotherapeutics that influence brain activity through the gut-brain axis
Clinical-stage neuroscience biotech developing gut-restricted neurotherapeutics that influence brain activity through the gut-brain axis. Its lead oral candidate DGX-001 targets AVPR1A receptors on gut enteroendocrine cells to modulate vagal signaling, with development focused on cognitive impairment and potential applications in neurodegenerative and psychiatric disorders. The pipeline also includes neuropeptides and next-generation peptide and small-molecule candidates for depression, anxiety,